Skip to main content

Peer Review reports

From: GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Original Submission
19 Jan 2017 Submitted Original manuscript
14 Jun 2017 Reviewed Reviewer Report - Joel Dubin
29 Jun 2017 Author responded Author comments - Jamie Oughton
Resubmission - Version 2
29 Jun 2017 Submitted Manuscript version 2
14 Jul 2017 Reviewed Reviewer Report - Joel Dubin
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
14 Jul 2017 Editorially accepted
26 Jul 2017 Article published 10.1186/s13063-017-2107-0

You can find further information about peer review here.

Back to article page